Taken together, because of DYRK1A’s interactions with several factors involved in PD and its multiple positions in regulating inflammation, we intend to test the therapeutic hypothesis that by reducing DYRK1A activity, it is possible to intervene in PD pathogenesis and to slow or stop disease progression. Here, DYRK1A is linked to Parkinson disease.